SCHEMBL1756262

SCHEMBL1756262

COC(=O)C(NC(=O)c1nc(-c2ccc(NC(=O)Nc3ccc(Cl)cc3F)cc2)cs1)C(C)C

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CSGALNACT1 Q8TDX6 6/20 0.58
DGAT1 O75907 3/20 0.47
ALDH1A1 P00352 3/20 0.44
POLB P06746 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
PSMD14 O00487 1/20 0.43
MAPT P10636 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
HTT P42858 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
MAPK1 P28482 1/20 0.42
RECQL P46063 1/20 0.42
ROCK1 Q13464 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11969052 1.00 CSGALNACT1 (0.58) CSGALNACT1DGAT1ALDH1A1POLBTDP1
SCHEMBL1756269 0.92 CSGALNACT1 (0.69) CSGALNACT1DGAT1
SCHEMBL1756310 0.92 CSGALNACT1 (0.69) CSGALNACT1DGAT1
SCHEMBL1756202 0.90 MEN1 (0.52) CSGALNACT1DGAT1ALDH1A1POLBMEN1
SCHEMBL11969065 0.90 MEN1 (0.52) CSGALNACT1DGAT1ALDH1A1POLBMEN1
SCHEMBL1756355 0.86 MEN1 (0.56) CSGALNACT1DGAT1ALDH1A1MEN1KMT2A
SCHEMBL1756270 0.86 MEN1 (0.56) CSGALNACT1DGAT1ALDH1A1MEN1KMT2A
SCHEMBL1756227 0.86 DGAT1 (0.66) CSGALNACT1DGAT1ALDH1A1NPSR1MEN1
SCHEMBL1756319 0.85 DGAT1 (0.64) CSGALNACT1DGAT1ALDH1A1NPSR1MEN1
SCHEMBL1756318 0.85 DGAT1 (0.64) CSGALNACT1DGAT1ALDH1A1NPSR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722901-B2 Carboxy oxazole or thiazole compounds as DGAT-1 inhibitors useful for the treatment of obesity Piramal Enterprises Limited (IN) 2014-05-13 US disclosed
EP-2496564-A2 HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS Piramal Life Sciences Limited (IN) 2012-09-12 EP disclosed
US-20120214854-A1 CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY Piramal Enterprises Limited (IN) 2012-08-23 US disclosed
WO-2011055289-A2 HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214854-A1 CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY DGAT1, DGAT2, DLAT CSGALNACT1 555/4885DGAT1 1/4885ALDH1A1 592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.